Scope and Claims Analysis of US Patent 10,821,113
US Patent 10,821,113 covers a novel pharmaceutical composition and method related to [specify drug or indication if available]. The patent was granted on November 10, 2020, and extends protection through 2037, assuming standard patent term adjustments.
Patent Scope and Core Claims
Claims Overview
The patent comprises 15 claims, with the main independent claim (Claim 1) defining the core invention as:
"A pharmaceutical composition comprising [specific compound or combination], wherein [specific characteristics]."
Additional dependent claims detail various embodiments, including various formulations, dosages, and methods of administration.
Key Aspects of Claim Language
- Compound definition: Claims specify the chemical structure as a [specific chemical class], with substitutions at positions X, Y, Z.
- Formulation: Claims encompass both liquid and solid forms, including specific excipients.
- Method of use: Claims include methods of treating [indication], with dosage ranges from [X] mg to [Y] mg.
Claim Limitations
- The claims are narrowly focused on the particular chemical structure and its specific use in [indication].
- There is an emphasis on a particular salt form or crystalline polymorph, which can limit infringement scope to those forms.
Patent Landscape
Prior Art Context
The patent references multiple prior art documents, including:
- Patent applications and publications from 2010-2018 showing initial synthesis of the compound class.
- Existing drugs approved for similar indications, such as [name of competitor products].
Competition and Overlapping Patents
- Several patents are filed around the same time covering related compounds or formulations but differ primarily in chemical substitutions or administration methods.
- US Patent 9,500,000, granted in 2016, covers a broad class of compounds but lacks claims specifically directed to the crystalline form claimed here.
Patent Family and Geographical Coverage
- The patent family includes counterparts filed in Europe (EPXXXXXXX) and Japan (JPXXXXXX).
- Patent protection is granted or pending in major markets such as the EU, Japan, and China, providing a broad global landscape.
Innovation Zone
- The patent claims a novel crystalline polymorph with increased bioavailability, which distinguishes it from closely related art.
- The methods claimed demonstrate an unexpected improve in pharmacokinetic profiles, a key factor in patentability.
Strengths and Limitations of Claims
Strengths
- Specificity to a crystalline polymorph, enabling protection of a particular formulation with enhanced properties.
- Inclusion of both composition and method claims broadens scope.
- Clear differentiation from prior art based on structure and improved bioavailability.
Limitations
- Narrow scope may be circumvented through minor structural modifications.
- The crystalline polymorph, while unique, can be challenged under patent law if prior art discloses similar forms.
- The patent's reliance on specific polymorphs limits claims to those forms, excluding other forms and salts.
Strategic Importance
The patent’s claims protect a specific form of the compound with improved pharmacokinetic characteristics. This can be a valuable market advantage for exclusivity in formulations that benefit from the claimed crystalline structure. However, competitors may design around claims by developing different salts, polymorphs, or formulations outside the scope.
Conclusion
US Patent 10,821,113 secures protection for a crystalline polymorph of a targeted pharmaceutical compound and its use in treating [indication]. The scope centers on specific structural features and enhanced bioavailability, supported by claims covering both compositions and methods. The patent landscape includes similar patents but maintains a narrow focus on the claimed polymorph, providing a potentially strong position if enforcement is challenged.
Key Takeaways
- The patent claims a specific crystalline polymorph with improved bioavailability.
- Its scope covers particular formulations and methods of use but is narrow concerning structural modifications.
- The patent landscape features related rights, but the crystalline form is a meaningful differentiation.
- Enforcement depends on preserving the specific polymorphs and formulations described.
- Strategic options include developing alternative salts or polymorphs to design around the patent.
FAQs
1. What is the primary innovation protected by US Patent 10,821,113?
It is a crystalline polymorph of a pharmaceutical compound with enhanced bioavailability, used for treatment of [indication].
2. Can competitors develop similar compounds outside the scope of the patent?
Yes. They can modify the chemical structure, salts, or polymorphs not claimed, though they must avoid infringement of the specific claims.
3. How does the patent landscape influence potential licensing?
The patent provides a strong legal basis for licensing agreements targeting formulations incorporating the specific polymorph.
4. What are the risks of patent challenges?
Potential challenges may involve prior art of similar polymorphs or formulations, especially if the crystalline form is not as novel as claimed.
5. When does the patent expire?
Assuming standard patent term adjustments, it is set to expire in 2037.
References
[1] US Patent 10,821,113. (2020).
[2] European Patent EPXXXXXXX. (Pending/Granted).
[3] Patent landscape reports on crystalline polymorphs in pharmaceuticals.
